Search results
Results from the WOW.Com Content Network
Federal regulators are increasingly approving medicines before studies have shown they work, leaving patients at risk of taking prescriptions that could harm but not help them.
The website Science-Based Medicine goes even further, claiming: "No other show on television can top The Dr. Oz Show for the sheer magnitude of bad health advice it consistently offers, all while giving everything a veneer of credibility." [3] What follows is a selection of claims lacking scientific evidence.
Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.
The company has also filed lawsuits against sellers falsely claiming to sell FDA-approved versions of the drug. For more CNN news and newsletters create an account at CNN.com Show comments
Women who are pregnant or breastfeeding should not take enasidenib because it may cause harm to a developing fetus or a newborn baby. [4] Enasidenib was approved for medical use in the United States in August 2017. [2] [4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [5]
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
In December 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved olaparib as monotherapy. [ 7 ] [ 14 ] [ 13 ] [ 11 ] [ 12 ] The FDA approval is in germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.